Table 2 ESBL prevalence over time, including bacterial species and identified ESBL genes of the ESBL-E

Evaluable cultures, n

516

558

560

502

393

425

425

373

367

4119

ESBL positive patients based on phenotype, n (%)

28 (5.4%)

39 (7.0%)

33 (5.9%)

16 (3.2%)

21 (5.3%)

25 (5.9%)

9 (2.1%)

18 (4.8%)

17 (4.6%)

206 (5.0%)

ESBL positive patients based on genotype, No.

25 (4.8%)

37(6.6%)

32 (5.7%)

14 (2.8%)

18 (4.6%)

24 (5.6%)

9 (2.1%)

15 (4.0%)

14 (3.8%)

188 (4.6%)

Patients with > 1 ESBL producing isolate, No.

4

0

1

0

0

0

2

0

1

8

ESBL producing isolates

Genetically confirmed ESBL isolates, No.

30

37

34

14

18

24

11

15

15

198

Escherichia coli, No.

25

29

30

12

15

18

10

10

9

158 (79.8%)

Klebsiella pneumoniae, No.

5

4

2

2

2

2

0

2

3

22 (11.1%)

Enterobacter cloacae complex, No.

0

3

2

0

1

4

0

3

2

15 (7.6%)

Other species, No.

0

1

0

0

0

0

1

0

1

3 (1.5%)

ESBL genes

Isolates with > 1 ESBL gene, No.

3

4

3

0

1

2

1

1

2

17 (8.6%)

Total ESBL genes identified, No.

33

41

37

14

19

26

12

16

17

215

CTX-M family, No.

30

36

32

11

15

21

10

14

14

183 (85.1%)

SHV family, No.

2

5

4

2

2

3

1

1

3

23 (10.7%)

TEM family, No.

0

0

1

1

2

2

0

0

0

6 (2.8%)

Other, No.

0

0

0

0

0

0

1

0

0

1 (0.5%)